SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micros strong quarterly results and raised full-year outlook, driven by AI-server demand, dominate discussion. Bulls view the results as validation and see the shares as undervalued, while skeptics cite margin, cash-flow and credibility concernsand question the muted stock reaction.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Midterm election results and the prospect of Democrats gaining control of Congress dominate discussion, with traders debating whether a potential setback for Trump would hurt DJT or ease political risk. Bears expect pressure if Republicans lose ground, while some bulls argue the election may be a routine midterm rebuke and point to the stocks rebound.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMDs stronger-than-expected quarterly results and upbeat outlook, driven by surging AI data-center demand, are fueling a sharp rebound and optimism that semiconductor demand remains strong. Bulls are celebrating the growth outlook and squeeze on bearish bets, while skeptics question the valuation, weaker cash flow, and reliance on data-center expansion.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

A letter from 28 HOPE-3 investigators urging FDA approval of deramiocel has renewed optimism ahead of the agencys Nov. 22 decision for the Duchenne muscular dystrophy therapy. Many traders see the physicians support as strengthening the case for approval and anticipate short covering, while others remain wary of the FDAs prior concerns about the trial data and the binary outcome.

Arista Networks, Inc. engages in the development, marketing, and sale of cloud networking solutions. Its solutions include EOS, a set of network applications, and Gigabit Ethernet switching and routing platforms. Its product categories include core, cognitive adjacencies, and cognitive networks. The company was founded by Andreas Bechtolsheim, David Cheriton, and Kenneth Duda in November 2004 and is headquartered in Santa Clara, CA.

Arista Networks Inc

Aristas quarterly results beat expectations, and its next-quarter guidance came in well above forecasts, with traders pointing to accelerating AI-networking demand as the key driver. The strong report sparked a sharp rally and bullish calls for further gains, though some caution that elevated valuation and volatile post-earnings trading could bring profit-taking.

Churchill Capital Corp. XI is a blank check company. It was formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded by Michael Stuart Klein on June 4, 2025 and is headquartered in New York, NY.

Churchill Capital Corp XI - Ordinary Shares - Class A

Attention centers on Agility Robotics humanoid-robot exposure, with traders comparing it to Unitrees high-profile IPO and citing U.S. restrictions on Chinese robot imports as potential tailwinds. Bulls point to commercial deployments and major backers, while skeptics question the SPAC valuation, limited revenue, and ability to scale.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ chatter centers on a choppy tech-market rebound, with traders crediting strong AMD and SMCI results for renewed buying while debating whether the rally can hold. Midterm-election uncertainty and concerns about AI valuations and tech-sector weakness keep bearish views active.

Duolingo, Inc. is a language-learning website and mobile application, which engages in the development of a free language learning website and crowd sourced text translation platform. It offers Duolingo for Schools, a free, web-based tool that aims to make it easier for teachers to use the Duolingo platform in a structured learning environment, and English Test, an online, on-demand assessment of English proficiency. The company was founded by Luis von Ahn and Severin Hacker in 2011 and is headquartered in Pittsburgh, PA.

Duolingo Inc - Ordinary Shares - Class A

Duolingo Inc

Duolingos Q3 results and raised full-year guidance are driving discussion: traders point to accelerating user growth and revenue and bookings above expectations, while noting a slight EPS miss. Reactions are split, with optimism that AI can improve the product countered by concerns about monetization, valuation and the shares post-earnings pullback.

Astera Labs, Inc. provides rack-scale AI infrastructure through purpose-built connectivity solutions. The company offers a range of semiconductor-based connectivity solutions designed to address bandwidth, latency, and reliability challenges in AI and cloud data centers. The company was founded by Jitendra Mohan, Casey Morrison, and Sanjay Gajendra in October 2017 and headquartered in San Jose, CA.

Astera Labs Inc.

Astera Labs Inc

Astera Labs strong quarterly results and raised outlook are drawing attention, but shares sold off despite the beat. Traders are debating whether the reaction reflects lofty valuation and concerns about AI-data-center spending or a buying opportunity, with dip-buyers pointing to continued growth in connectivity products.

Block, Inc. engages in creating ecosystems for distinct customer audiences. It operates through the following segments: Square and Cash App. The Square segment provides payment services, software solutions, hardware, and financial services to sellers. The Cash App segment includes the financial tools available to individuals within the mobile Cash App, including peer-to-peer payments, bitcoin and stock investments. The company was founded by Jack Patrick Dorsey and James Morgan McKelvey in February 2009 and is headquartered in Oakland, CA.

Block Inc - Ordinary Shares - Class A

Block Inc

Blocks Q3 earnings beat estimates and the company raised its 2026 profit outlook, drawing bullish calls on growth in Cash App and Square. Skeptics question the quality of the beat, pointing to Bitcoin-related gains, rising credit losses and expenses, while some traders say the shares have failed to sustain the positive reaction.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

PTC Therapeutics Board of Directors Authorizes $500 Million Share Repurchase Program

PTC Therapeutics Board of Directors Authorizes $500 Million Share Repurchase Program PTC Therapeutics Board of Directors Authorizes $500 Million Share Repurchase ProgramPR NewswireWARREN, N.J., Nov. 3, 2026 WARREN, N.J., Nov. 3, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today...

PTC Therapeutics to Participate in Upcoming Investor Conferences

PTC Therapeutics to Participate in Upcoming Investor Conferences PTC Therapeutics to Participate in Upcoming Investor ConferencesPR NewswireWARREN, N.J., Nov. 2, 2026 WARREN, N.J., Nov. 2, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will speak at...

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR NewswireWARREN, N.J., Oct. 30, 2026 WARREN, N.J., Oct. 30, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced...

PTC Therapeutics (PTCT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for PTC Therapeutics (PTCT) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

PTC Therapeutics (PTCT) Q3 Earnings and Revenues Surpass Estimates

PTC Therapeutics (PTCT) delivered earnings and revenue surprises of +258.82% and +15.02%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results

PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial ResultsPR NewswireWARREN, N.J., Oct. 29, 2026 Strong Q3 2026 performance with total revenue of $358 million, including $276...

Liquidia Corporation (LQDA) Earnings Expected to Grow: Should You Buy?

Liquidia Corporation (LQDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate PTC Therapeutics (PTCT) to Report a Decline in Earnings: What to Look Out for

PTC Therapeutics (PTCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PTC Therapeutics to Report Third Quarter 2026 Financial Results on Thursday, Oct. 29, 2026

PTC Therapeutics to Report Third Quarter 2026 Financial Results on Thursday, Oct. 29, 2026 PTC Therapeutics to Report Third Quarter 2026 Financial Results on Thursday, Oct. 29, 2026PR NewswireWARREN, N.J., Oct. 15, 2026WARREN, N.J., Oct. 15, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ...

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR NewswireWARREN, N.J., Sept. 25, 2026 WARREN, N.J., Sept. 25, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced...

• Reported GAAP EPS of -$0.62 down -410.00% YoY
• Reported revenue of $357.81M up 69.57% YoY
• PTC Therapeutics increased full-year 2026 expected total revenue to $1.29 to $1.32B and raised product revenue guidance to $960 to $990M; GAAP expense guidance remains $775 to $815M.

PTC Therapeutics reported a Q3 2026 net loss versus prior-year net income, lower Translarna and Emflaza revenues versus Q3 2025, and risks to maintaining Translarna marketing authorization.

PTC Therapeutics reported Sephience Q3 2026 revenue of $181.9M, 20% growth versus Q2 and over 2,000 active patients; ST-920 BLA submission is expected in Q4 2026, and votoplam's Phase 3 study is enrolling.

PTC Therapeutics, Inc. is a biopharmaceutical company, which focuses on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The company was founded by Allan Steven Jacobson and Stuart Walter Peltz on March 31, 1998 and is headquartered in Warren, NJ.

PTC Therapeutics Inc

PTC Therapeutics Stock In The Spotlight After FDA Refuses Approval For Drug To Treat Neurodegenerative Disease, Analysts Are Divided

Equity

Neutral Sentiment

PTC Therapeutics, Inc. (PTCT) said on Tuesday that the U.S. Food and Drug Administration refused to approve its application for Vatiquinone for the treatment of children and adults living with Friedreich's ataxia.CEO Matthew B. Klein said that the company is disappointed by the FDA’s decision and plans to meet with the agency to discuss potential steps to address the issues flagged in its complete response letter to the company.In its <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.ptcbio.com/news-releases/news-release-details/ptc-therapeutics-receives-complete-response-letter-vatiquinone">letter</a>, the FDA stated that substantial evidence of efficacy was not demonstrated for Vatiquinone and that an additional adequate and well-controlled study would be needed to support application resubmission. Friedreich's ataxia (FA) is a rare, inherited neurodegenerative disease that primarily affects the nervous system, causing progressive damage to the spinal cord, peripheral nerves, and cerebellum. This leads to impaired muscle coordination, balance problems, and other neurological symptoms.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/PTCT">PTCT</a> jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:627/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_19_at_12_18_34_PM_png_b76ebe8504.webp" alt="PTCT's Sentiment Meter and Message Volume as of 12:18 p.m. ET on Aug. 19, 2025 | Source: Stocktwits" width="627" height="61"><figcaption>PTCT's Sentiment Meter and Message Volume as of 12:18 p.m. ET on Aug. 19, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user expressed surprise at the stock trading in the green despite the news.<stembedurl>https://stocktwits.com/deadlypants/message/625768448</stembedurl>TD Cowen analyst Joseph Thome lowered their price target on PTC Therapeutics to $50 from $56 while keeping a ‘Hold’ rating on the shares following the company’s update. The firm removed Friedreich's ataxia from its model and believes a second successful late-stage study will likely be required for approval.RBC Capital, which has an ‘Outperform’ rating and $63 price target on the stock, meanwhile, believes this was generally expected and already baked into the stock. The firm said that it would still buy the company's shares, according to TheFly.Jefferies analyst Kelly Shi also lowered the firm's price target on PTC Therapeutics to $63 from $64 while keeping a ‘Buy’ rating on the shares. The letter "didn't come in as a surprise to us," said the analyst, who calls the regulatory update "a clearing event" that allows investors to now focus on the launch of a treatment for phenylketonuria.&nbsp;PTCT stock is up by 14% this year and by about 50% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/iovance-stock-rises-on-health-canada-approval-for-cancer-immunotherapy/chsgV4qRdW2">Iovance Stock Rises 4% On Health Canada Approval For Cancer Immunotherapy: Retail Thinks ‘Patience Will Pay Off’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a PTC Therapeutics company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

The FDA stated that substantial evidence of efficacy was not demonstrated for Vatiquinone and that an additional adequate and well-controlled study would be needed to support application resubmission.

Current Price	$68.12
Prev Close	$60.88
Open	$64.14
Dividend Yield	0.00%
50-Day Moving Average	$65.18
Beta	1.07
Avg. Volume	1.08M
PE Ratio	-43.23

52-Week High	$90.87
52-Week Low	$58.80
Market Capitalization	$5.09B
EPS (Annual)	$7.78
Price to Book	-26.60
Revenue Per Employee	$1.75M

Feed

News

Sentiment

Earnings

Fundamentals

Info

PTCT Fundamentals